Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 02
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Akebia Therapeutics Inc
AKBA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.8670
-0.004
-0.46%
Ult. Agg.: Oct 2, 12:03 PM
$0.8820
0.011
1.26%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Akebia Therapeutics Financials
Akebia Therapeutics (AKBA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Akebia Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $49.128M Beat $48.861M Estimate
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $49.128 million which beat
Benzinga Newsdesk
PRO
Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 200 percent decrease over earnings of $0.03 per share from the same period last year.
Benzinga Newsdesk
Akebia Therapeutics Q4 Earnings Report: What Investors Need to Know
Benzinga Insights
PRO
Akebia Therapeutics Q4 EPS $(0.05) Misses $(0.03) Estimate, Sales $57.620M Beat $48.373M Estimate.
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 85.19 percent. This is a 50 percent increase over losses of $(0.10) per share
Benzinga Newsdesk
Earnings Scheduled For February 26, 2026
Benzinga Insights
Uncovering Potential: Akebia Therapeutics's Earnings Preview
Benzinga Insights
